Celcuity reported that two regimens using its experimental pan–PI3K/mTOR inhibitor gedatolisib met success criteria in PIK3CA-mutant patients in a Phase 3 breast cancer trial, setting up a second FDA submission. The company said the results again supported the use of gedatolisib across the targeted patient population. The development matters for PI3K pathway competitors because it adds another readout from an ongoing push to convert pathway biology into label expansion. A second submission would extend Celcuity’s regulatory cadence beyond its prior FDA engagement. Separately, the newsletter notes that the story sits alongside broader pipeline and financing activity in the sector, underscoring investor appetite for mechanism-driven oncology franchises that can generate multiple filing opportunities. If FDA accepts the package efficiently, it could accelerate decisions for patients with limited targeted options in PIK3CA-driven disease.